6 results on '"Tsuji, Shuhei"'
Number of results to display per page
Search Results
2. Prognostic Impact of Aortic Valve Area in Conservatively Managed Patients With Asymptomatic Severe Aortic Stenosis With Preserved Ejection Fraction
- Author
-
Kanamori, Norio, primary, Taniguchi, Tomohiko, additional, Morimoto, Takeshi, additional, Watanabe, Hirotoshi, additional, Shiomi, Hiroki, additional, Ando, Kenji, additional, Murata, Koichiro, additional, Kitai, Takeshi, additional, Kawase, Yuichi, additional, Izumi, Chisato, additional, Miyake, Makoto, additional, Mitsuoka, Hirokazu, additional, Kato, Masashi, additional, Hirano, Yutaka, additional, Matsuda, Shintaro, additional, Nagao, Kazuya, additional, Inada, Tsukasa, additional, Mabuchi, Hiroshi, additional, Takeuchi, Yasuyo, additional, Yamane, Keiichiro, additional, Toyofuku, Mamoru, additional, Ishii, Mitsuru, additional, Minamino‐Muta, Eri, additional, Kato, Takao, additional, Inoko, Moriaki, additional, Ikeda, Tomoyuki, additional, Komasa, Akihiro, additional, Ishii, Katsuhisa, additional, Hotta, Kozo, additional, Higashitani, Nobuya, additional, Kato, Yoshihiro, additional, Inuzuka, Yasutaka, additional, Maeda, Chiyo, additional, Jinnai, Toshikazu, additional, Morikami, Yuko, additional, Saito, Naritatsu, additional, Minatoya, Kenji, additional, Aoyama, Takeshi, additional, Kimura, Takeshi, additional, Sakata, Ryuzo, additional, Imai, Masao, additional, Tazaki, Junichi, additional, Toyota, Toshiaki, additional, Higami, Hirooki, additional, Kawaji, Tetsuma, additional, Shirai, Shinichi, additional, Korai, Kengo, additional, Arita, Takeshi, additional, Miura, Shiro, additional, Yamaji, Kyohei, additional, Kim, Kitae, additional, Iwasaki, Keiichiro, additional, Miyawaki, Hiroshi, additional, Misao, Ayumi, additional, Kuwayama, Akimune, additional, Ohya, Masanobu, additional, Shimada, Takenobu, additional, Amano, Hidewo, additional, Amano, Masashi, additional, Takahashi, Yusuke, additional, Yoshikawa, Yusuke, additional, Nishimura, Shunsuke, additional, Kuroda, Maiko, additional, Mizoguchi, Tetsu, additional, Yokomatsu, Takafumi, additional, Kushiyama, Akihiro, additional, Yaku, Hidenori, additional, Watanabe, Toshimitsu, additional, Sugioka, Sachiko, additional, Takahashi, Naoki, additional, Fukuchi, Kohei, additional, Takeda, Teruki, additional, Sakaguchi, Tomoko, additional, Maeda, Keiko, additional, Yamaji, Masayuki, additional, Maenaka, Motoyoshi, additional, Tadano, Yutaka, additional, Motooka, Makoto, additional, Nishikawa, Ryusuke, additional, Kawato, Mitsunori, additional, Kinoshita, Minako, additional, Aida, Kenji, additional, Takahashi, Kousuke, additional, Ko, Euihong, additional, Masunaga, Nobutoyo, additional, Ogawa, Hisashi, additional, Iguchi, Moritake, additional, Unoki, Takashi, additional, Takabayashi, Kensuke, additional, Hamatani, Yasuhiro, additional, Yamashita, Yugo, additional, Tsuji, Shuhei, additional, Nishio, Soji, additional, Seki, Jyunya, additional, Yamada, Miho, additional, Kawamoto, Akira, additional, Sogabe, Kouji, additional, Tachiiri, Michiya, additional, Matsumura, Yukiko, additional, Ota, Chihiro, additional, Minakata, Kenji, additional, Hanyu, Michiya, additional, Yamazaki, Fumio, additional, Koyama, Tadaaki, additional, Komiya, Tatsuhiko, additional, Yamanaka, Kazuo, additional, Nishiwaki, Noboru, additional, Nakajima, Hiroyuki, additional, Ohnaka, Motoaki, additional, Osada, Hiroaki, additional, Meshii, Katsuaki, additional, Saga, Toshihiko, additional, Onoe, Masahiko, additional, Kitayama, Hitoshi, additional, Nakayama, Shogo, additional, Sakaguchi, Genichi, additional, Iwakura, Atsushi, additional, Shiraga, Kotaro, additional, Ueyama, Koji, additional, Fujiwara, Keiichi, additional, Fukumoto, Atsushi, additional, Miwa, Senri, additional, Nishizawa, Junichiro, additional, Kitano, Mitsuru, additional, Nakatsuma, Kenji, additional, and Sasa, Tomoki, additional
- Published
- 2019
- Full Text
- View/download PDF
3. Prognostic Impact of Peak Aortic Jet Velocity in Conservatively Managed Patients With Severe Aortic Stenosis: An Observation From the CURRENT AS Registry
- Author
-
Nakatsuma, Kenji, primary, Taniguchi, Tomohiko, additional, Morimoto, Takeshi, additional, Shiomi, Hiroki, additional, Ando, Kenji, additional, Kanamori, Norio, additional, Murata, Koichiro, additional, Kitai, Takeshi, additional, Kawase, Yuichi, additional, Izumi, Chisato, additional, Miyake, Makoto, additional, Mitsuoka, Hirokazu, additional, Kato, Masashi, additional, Hirano, Yutaka, additional, Matsuda, Shintaro, additional, Inada, Tsukasa, additional, Nagao, Kazuya, additional, Murakami, Tomoyuki, additional, Takeuchi, Yasuyo, additional, Yamane, Keiichiro, additional, Toyofuku, Mamoru, additional, Ishii, Mitsuru, additional, Minamino‐Muta, Eri, additional, Kato, Takao, additional, Inoko, Moriaki, additional, Ikeda, Tomoyuki, additional, Komasa, Akihiro, additional, Ishii, Katsuhisa, additional, Hotta, Kozo, additional, Higashitani, Nobuya, additional, Kato, Yoshihiro, additional, Inuzuka, Yasutaka, additional, Maeda, Chiyo, additional, Jinnai, Toshikazu, additional, Morikami, Yuko, additional, Saito, Naritatsu, additional, Minatoya, Kenji, additional, Kimura, Takeshi, additional, Imai, Masao, additional, Tazaki, Junichi, additional, Toyota, Toshiaki, additional, Higami, Hirooki, additional, Kawaji, Tetsuma, additional, Shirai, Shinichi, additional, Korai, Kengo, additional, Arita, Takeshi, additional, Miura, Shiro, additional, Yamaji, Kyohei, additional, Kim, Kitae, additional, Iwasaki, Keiichiro, additional, Miyawaki, Hiroshi, additional, Misao, Ayumi, additional, Kuwayama, Akimune, additional, Ohya, Masanobu, additional, Shimada, Takenobu, additional, Amano, Hidewo, additional, Amano, Masashi, additional, Takahashi, Yusuke, additional, Yoshikawa, Yusuke, additional, Nishimura, Shunsuke, additional, Kuroda, Maiko, additional, Mizoguchi, Tetsu, additional, Yokomatsu, Takafumi, additional, Kushiyama, Akihiro, additional, Yaku, Hidenori, additional, Watanabe, Toshimitsu, additional, Sugioka, Sachiko, additional, Takahashi, Naoki, additional, Fukuchi, Kohei, additional, Mabuchi, Hiroshi, additional, Takeda, Teruki, additional, Sakaguchi, Tomoko, additional, Yamaji, Masayuki, additional, Maenaka, Motoyoshi, additional, Tadano, Yutaka, additional, Motooka, Makoto, additional, Nishikawa, Ryusuke, additional, Kawato, Mitsunori, additional, Kinoshita, Minako, additional, Aida, Kenji, additional, Takahashi, Kousuke, additional, Ko, Euihong, additional, Masunaga, Nobutoyo, additional, Ogawa, Hisashi, additional, Iguchi, Moritake, additional, Unoki, Takashi, additional, Takabayashi, Kensuke, additional, Hamatani, Yasuhiro, additional, Yamashita, Yugo, additional, Tsuji, Shuhei, additional, Nishio, Soji, additional, Seki, Jyunya, additional, Yamada, Miho, additional, Kawamoto, Akira, additional, Sogabe, Kouji, additional, Tachiiri, Michiya, additional, Matsumura, Yukiko, additional, Ota, Chihiro, additional, Sakata, Ryuzo, additional, Minakata, Kenji, additional, Hanyu, Michiya, additional, Yamazaki, Fumio, additional, Koyama, Tadaaki, additional, Komiya, Tatsuhiko, additional, Yamanaka, Kazuo, additional, Nishiwaki, Noboru, additional, Ohnaka, Motoaki, additional, Osada, Hiroaki, additional, Meshii, Katsuaki, additional, Saga, Toshihiko, additional, Kitayama, Hitoshi, additional, Nakayama, Shogo, additional, Sakaguchi, Genichi, additional, Iwakura, Atsushi, additional, Shiraga, Kotaro, additional, Ueyama, Koji, additional, Fujiwara, Keiichi, additional, Fukumoto, Atsushi, additional, Miwa, Senri, additional, Nishizawa, Junichiro, additional, Kitano, Mitsuru, additional, Watanabe, Hirotoshi, additional, and Sasa, Tomoki, additional
- Published
- 2017
- Full Text
- View/download PDF
4. Incidence of Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2.
- Author
-
Ikeda N, Yamashita Y, Morimoto T, Chatani R, Kaneda K, Nishimoto Y, Kobayashi Y, Ikeda S, Kim K, Inoko M, Takase T, Tsuji S, Oi M, Takada T, Otsui K, Sakamoto J, Ogihara Y, Inoue T, Usami S, Chen PM, Togi K, Koitabashi N, Hiramori S, Doi K, Mabuchi H, Tsuyuki Y, Murata K, Takabayashi K, Nakai H, Sueta D, Shioyama W, Dohke T, and Kimura T
- Subjects
- Humans, Female, Male, Incidence, Aged, Middle Aged, Japan epidemiology, Risk Factors, Chronic Disease, Anticoagulants adverse effects, Anticoagulants administration & dosage, Anticoagulants therapeutic use, Administration, Oral, Risk Assessment, Time Factors, Pulmonary Embolism epidemiology, Pulmonary Embolism drug therapy, Pulmonary Embolism diagnosis, Registries, Hypertension, Pulmonary epidemiology, Hypertension, Pulmonary drug therapy, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary etiology
- Abstract
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening complication post-acute pulmonary embolism (PE). The assessment of CTEPH incidence and risk factors post-acute PE in the era of direct oral anticoagulants remains insufficient., Methods and Results: The COMMAND VTE Registry-2 (contemporary management and outcomes in patients with venous thromboembolism registry-2) is a multicenter registry that recruited consecutive patients with acute symptomatic venous thromboembolism from 31 centers across Japan. The primary outcome was to demonstrate the detection rate of CTEPH after acute PE in routine clinical practice. Out of the 5197 patients with venous thromboembolism included in the COMMAND VTE Registry-2, 2787 were diagnosed with acute PE. Following a median follow-up duration of 747 days, 48 cases of CTEPH were detected, and the cumulative diagnosis of CTEPH in routine clinical practice was 2.3% at 3 years. Independent risk factors for the detection of CTEPH by multivariable Cox regression analysis included women (hazard ratio [HR] 2.09 [95% CI, 1.05-4.14]), longer interval from symptom onset to diagnosis of PE (each 1 day, HR 1.04 [95% CI, 1.01-1.07]), hypoxemia at diagnosis (HR 2.52 [95% CI, 1.26-5.04]), right heart load (HR 9.28 [95% CI, 3.19-27.00]), lower D-dimer value (each 1 μg/mL, HR 0.96 [95% CI, 0.92-0.99]), and unprovoked PE (HR 2.77 [95% CI, 1.22-6.30])., Conclusions: In the direct oral anticoagulant era, the cumulative diagnosis of CTEPH after acute PE was 2.3% at 3 years, and several independent risk factors for CTEPH were identified, which could be useful for screening a high-risk population after acute PE.
- Published
- 2024
- Full Text
- View/download PDF
5. Selection of Home Treatment and Identification of Low-Risk Patients With Pulmonary Embolism Based on Simplified Pulmonary Embolism Severity Index Score in the Era of Direct Oral Anticoagulants.
- Author
-
Nishikawa R, Yamashita Y, Morimoto T, Kaneda K, Chatani R, Nishimoto Y, Ikeda N, Kobayashi Y, Ikeda S, Kim K, Inoko M, Takase T, Tsuji S, Oi M, Takada T, Otsui K, Sakamoto J, Ogihara Y, Inoue T, Usami S, Chen PM, Togi K, Koitabashi N, Hiramori S, Doi K, Mabuchi H, Tsuyuki Y, Murata K, Takabayashi K, Nakai H, Sueta D, Shioyama W, Dohke T, Ono K, and Kimura T
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Risk Assessment, Administration, Oral, Japan epidemiology, Risk Factors, Home Care Services, Patient Selection, Aged, 80 and over, Treatment Outcome, Pulmonary Embolism drug therapy, Pulmonary Embolism mortality, Pulmonary Embolism diagnosis, Severity of Illness Index, Registries, Anticoagulants administration & dosage, Anticoagulants therapeutic use, Anticoagulants adverse effects
- Abstract
Background: The simplified Pulmonary Embolism Severity Index (sPESI) score could help identify low-risk patients with pulmonary embolism for home treatment. However, the application of the sPESI score and selection for home treatment have not been fully evaluated in the direct oral anticoagulants era., Methods and Results: The COMMAND VTE (Contemporary Management and Outcomes in Patients With Venous Thromboembolism) Registry-2 is a multicenter registry enrolling consecutive patients with acute symptomatic venous thromboembolism. The current study population consists of 2496 patients with hemodynamically stable pulmonary embolism (2100 patients [84%] treated with direct oral anticoagulants), who were divided into 2 groups: sPESI scores of 0 and ≥1. We investigated the 30-day mortality, home treatment prevalence, and factors predisposing to home treatment using the Kaplan-Meier method and logistic regression model. Patients with an sPESI score of 0 accounted for 612 (25%) patients, and only 17% among 532 patients with out-of-hospital pulmonary embolism were treated at home. The cumulative 30-day mortality was lower in patients with an sPESI score of 0 than the score of ≥1 (0% and 4.8%, log-rank P <0.001). There was no patient with 30-day mortality with an sPESI score of 0. Independent factors for home treatment among out-of-hospital pulmonary embolism patients with an sPESI score of 0 were no transient risk factors for venous thromboembolism, no cardiac biomarker elevation, and direct oral anticoagulants use in the acute phase., Conclusions: The 30-day mortality rate was notably low in an sPESI score of 0. Nevertheless, only a minority of patients with an sPESI score of 0 were treated at home between 2015 and 2020 after the introduction of direct oral anticoagulants for venous thromboembolismin Japan.
- Published
- 2024
- Full Text
- View/download PDF
6. Temporal Changes in Long-Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era.
- Author
-
Kaneda K, Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Ikeda N, Kobayashi Y, Ikeda S, Kim K, Inoko M, Takase T, Tsuji S, Oi M, Takada T, Otsui K, Sakamoto J, Ogihara Y, Inoue T, Usami S, Chen PM, Togi K, Koitabashi N, Hiramori S, Doi K, Mabuchi H, Tsuyuki Y, Murata K, Takabayashi K, Nakai H, Sueta D, Shioyama W, Dohke T, Nishikawa R, Ono K, and Kimura T
- Subjects
- Humans, Male, Female, Japan epidemiology, Aged, Middle Aged, Administration, Oral, Incidence, Time Factors, Treatment Outcome, Risk Factors, Venous Thromboembolism epidemiology, Venous Thromboembolism drug therapy, Venous Thromboembolism diagnosis, Warfarin adverse effects, Warfarin therapeutic use, Registries, Anticoagulants adverse effects, Anticoagulants therapeutic use, Recurrence, Hemorrhage chemically induced, Hemorrhage epidemiology, Factor Xa Inhibitors adverse effects, Factor Xa Inhibitors therapeutic use
- Abstract
Background: There have been limited data on the changes in clinical outcomes after the introduction of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) in real clinical practice. We evaluated the changes in management strategies and long-term outcomes from the warfarin era to the DOAC era., Methods and Results: We compared the 2 series of multicenter COMMAND VTE (Contemporary Management and Outcomes in Patients With Venous Thromboembolism) registries in Japan enrolling consecutive patients with acute symptomatic VTE: Registry 1: 3027 patients in the warfarin era (2010-2014) and Registry 2: 5197 patients in the DOAC era (2015-2020). The prevalence of DOAC use increased more in Registry 2 than in the Registry 1 (Registry 1: 2.6% versus Registry 2: 79%, P <0.001). The cumulative 5-year incidence of recurrent VTE was significantly lower in Registry 2 than in Registry 1 (10.5% versus 9.5%, P =0.02), and the risk reduction of recurrent VTE in Registry 2 remained significant even after adjusting the confounders (hazard ratio [HR], 0.78 [95% CI, 0.65-0.93]; P =0.005). The cumulative 5-year incidence of major bleeding was not significantly different between the 2 registries (12.1% versus 13.7%, P =0.26), and the risk of major bleeding between the 2 registries was not significantly different even after adjusting the confounders (HR, 1.04 [95% CI, 0.89-1.21]; P =0.63)., Conclusions: Along with the shift from warfarin to DOACs, there was a lower risk of recurrent VTE in the DOAC era than in the warfarin era, whereas there was no apparent change in the risk of major bleeding, which might still be an unmet need even in the DOAC era.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.